Cargando…
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
BACKGROUND: While programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) checkpoint inhibitors have activity in a proportion of patients with advanced bladder cancer, strongly predictive and prognostic biomarkers are still lacking. In this study, we evaluated PD-L1 protein expression on cir...
Autores principales: | Anantharaman, Archana, Friedlander, Terence, Lu, David, Krupa, Rachel, Premasekharan, Gayatri, Hough, Jeffrey, Edwards, Matthew, Paz, Rosa, Lindquist, Karla, Graf, Ryon, Jendrisak, Adam, Louw, Jessica, Dugan, Lyndsey, Baird, Sarah, Wang, Yipeng, Dittamore, Ryan, Paris, Pamela L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034508/ https://www.ncbi.nlm.nih.gov/pubmed/27658492 http://dx.doi.org/10.1186/s12885-016-2758-3 |
Ejemplares similares
-
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
por: Fujii, Takeo, et al.
Publicado: (2017) -
Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors
por: Lindquist, Karla J., et al.
Publicado: (2017) -
Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
por: Lu, David, et al.
Publicado: (2020) -
Measurement of copy number variation in single cancer cells using rapid-emulsification digital droplet MDA
por: Kim, Samuel C., et al.
Publicado: (2017) -
PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)